Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet
; 392(10165): 2705-2717, 2019 12 22.
Article
in En
| MEDLINE
| ID: mdl-30554783
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polyethylene Glycols
/
Fibroblast Growth Factors
/
Non-alcoholic Fatty Liver Disease
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2019
Document type:
Article
Affiliation country:
Country of publication: